

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau902015-8
720

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07K 7/23, A61K 38/09	A1	(11) International Publication Number: WO 98/21229 (43) International Publication Date: 22 May 1998 (22.05.98)
(21) International Application Number: PCT/EP97/06322 (22) International Filing Date: ✓ 12 November 1997 (12.11.97) (30) Priority Data: 96402441.8 ✓ 14 November 1996 (14.11.96) EP (34) Countries for which the regional or international application was filed: FR et al. (71) Applicant (for all designated States except US): LABO- RATOIRE THERAMEX [MC/MC]; 6, avenue Prince Héréditaire Albert, MC-98000 Monaco (MC). (72) Inventors; and (75) Inventors/Applicants (for US only): DELANSORNE, Rémi [FR/FR]; 7ter, avenue Edith Cavell, F-06000 Nice (FR). PARIS, Jacques [FR/FR]; Bâtiment E1, 31, avenue Cap de Croix, F-06100 Nice (FR). (74) Agents: NEVANT, Marc et al.; Cabinet Beau de Loménie, 158, rue de l'Université, F-75340 Paris Cedex 07 (FR).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: CONFORMATIONALLY CONSTRAINED LH-RH ANALOGUES, THEIR USES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM (57) Abstract The invention relates to LH-RH peptide analogues with excellent affinity for LH-RH receptors, of the formula: V-W-X-SPL-Y-Pro-Z where V, W, X, SPL, Y and Z are as defined in the specification. The invention also relates to the uses of said peptide analogues and to the pharmaceutical compositions containing them.		